Brain Iron Toxicity and Neurodegeneration

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-09-10

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A longitudinal observational neuroimaging study of individuals with Early Onset Alzheimer's disease during the prodromal phase, and matched control group - Ultrahigh Field MRI study at 7T

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multi-modal Neuroimaging in Alzheimer's Disease

NCT01638949

Alzheimer's Disease

COMPLETED NA

Magnetic Resonance Imaging (MRI) of Brain Iron in Neurodegenerative Disease

NCT00249080

Neurodegenerative Diseases Mild Cognitive Impairment

COMPLETED

[18F]AV45(Aβ) and [18F]AV1451(Tau)PET/CT in the Diagnosis of Early Pathological Changes of Alzheimer's Disease

NCT06833645

Alzheimer's Disease

RECRUITING

Metabolic Characterization of Alzheimer's Disease and Frontotemporal Dementia by 23Na-MRI and FDG-PET

NCT07100470

FTD AD Healthy Controls

NOT_YET_RECRUITING NA

Neuroinflammation and Cognitive Decline in Alzheimer Disease

NCT02377206

Alzheimer Disease

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study aims to determine whether high resolution MRI at 7T and Quantitative Susceptibility Mapping (QSM) can demonstrate a specific pattern of iron overload in strategically important areas of brain as a sensitive marker of pathological Alzheimer's disease i.e. patients with subjective or mild cognitive impairment associated with Amyloid or tau pathological state in the cerebrospinal fluid.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prodromal Alzheimer's Disease Mild Cognitive Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Alzheimer's disease

Patients with Early Onset Alzheimer's disease (with known cerebrospinal fluid Amyloid/tau status) during prodromal or mild phase will have MRI of the brain at 7T, neurocognitive assessments, and blood test to check APOe status.

Repeat neuroimaging and neurocognitive tests after one year.

MRI at 7T

Intervention Type OTHER

MRI at 7T

Control group

Age and gender matched individuals with normal cognition will have MRI of the brain at 7T, neurocognitive assessments and blood test to check APOe status.

Repeat neuroimaging, neurocognitive tests after one year.

MRI at 7T

Intervention Type OTHER

MRI at 7T

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MRI at 7T

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ability to provide informed consent
* Patients with pathological diagnosis of Alzheimer's disease according to the National Institute on Aging and Alzheimer's Association, NIA-AA, criteria (Alzheimer's group) or cognitively normal individuals within 1.5 standard deviation of normal in all tests (control group)

Exclusion Criteria

* Lack of mental capacity to consent to study involvement
* Not speaking English before age 5 years
* Learning disability
* Schizophrenia
* Substance misuse
* Implanted devices not certified as compatible with ultra-high field MRI (e.g. cardiac pacemaker)
* Pregnancy

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No